Floatz logo

METHADONE

Eye Cancer

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Eye Cancer cohort.

Asset / SponsorPhaseRating
Nbm-Bmx
Novelwise Pharmaceutical Corporation
Phase 1/2CCC
Mage-12 Peptide Vaccine
National Cancer Institute (NCI)
Phase 1CC

Same molecule, other indications

METHADONE is also rated in:

substance-related disorderDormant
BBB
Indicative ·
78 / 100
View asset →
chronic pain syndromeDormant
BBB
Indicative ·
75 / 100
View asset →
Opiate AddictionDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →